Rhus vernicifluaStokes against Advanced Cancer: A Perspective from the Korean Integrative Cancer Center
Open Access
- 17 November 2011
- journal article
- review article
- Published by Hindawi Limited in Journal of Biomedicine and Biotechnology
- Vol. 2012, 1-7
- https://doi.org/10.1155/2012/874276
Abstract
Active anticancer molecules have been searched from natural products; many drugs were developed from either natural products or their derivatives following the conventional pharmaceutical paradigm of drug discovery. However, the advances in the knowledge of cancer biology have led to personalized medicine using molecular-targeted agents which create new paradigm. Clinical benefit is dependent on individual biomarker and overall survival is prolonged through cytostatic rather than cytotoxic effects to cancer cell. Therefore, a different approach is needed from the single lead compound screening model based on cytotoxicity. In our experience, theRhus vernicifluastoke (RVS) extract traditionally used for cancer treatment is beneficial to some advanced cancer patients though it is herbal extract not single compound, and low cytotoxic in vitro. The standardized RVS extract's action mechanisms as well as clinical outcomes are reviewed here. We hope that these preliminary results would stimulate different investigation in natural products from conventional chemicals.Keywords
This publication has 30 references indexed in Scilit:
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Efficacy and Safety of Rhus verniciflua Stokes Extracts in Patients with Previously Treated Advanced Non-Small Cell Lung CancerResearch in Complementary Medicine, 2011
- Rhus verniciflua Stokes extract as a potential option for treatment of metastatic renal cell carcinoma: report of two casesAnnals of Oncology, 2010
- A Case of Recurred Hepatocellular Carcinoma Refractory to Doxorubicin After Liver Transplantation Showing Response to Herbal Medicine Product, Rhus verniciflua Stokes ExtractIntegrative Cancer Therapies, 2010
- Flavonol-rich RVHxR from Rhus verniciflua Stokes and its major compound fisetin inhibits inflammation-related cytokines and angiogenic factor in rheumatoid arthritic fibroblast-like synovial cells and in vivo modelsInternational Immunopharmacology, 2009
- A phase I/II trial of a polysaccharide extract from Grifola frondosa (Maitake mushroom) in breast cancer patients: immunological effectsZeitschrift für Krebsforschung und Klinische Onkologie, 2009
- Decursin and decursinol angelate inhibit VEGF-induced angiogenesis via suppression of the VEGFR-2-signaling pathwayCarcinogenesis: Integrative Cancer Research, 2009
- The NCI60 human tumour cell line anticancer drug screenNature Reviews Cancer, 2006
- Predicting benefit from anti-angiogenic agents in malignancyNature Reviews Cancer, 2006
- The chalcone butein from Rhus verniciflua Stokes inhibits clonogenic growth of human breast cancer cells co-cultured with fibroblastsBMC Complementary and Alternative Medicine, 2005